Alex Therapeutics’ platform approach to Digital Therapeutics, along with the passion, skill and dedication of the founder, John Drakenberg, presented an attractive case for Scale Capital. Digital Therapeutics has the potential to deliver critical health benefits in a scalable and cost-effective way, allowing treatments for underserved communities.
Alex Therapeutics is a digital therapeutics company based in Stockholm which designs and develops Software-as-a-Medical-Devices. With the proven “Alex DTx Platform”, expertise in artificial intelligence and evidence-based psychology, Alex Therapeutics is uniquely positioned to deliver cutting-edge and reliable digital therapeutics products. The company has treated tens of thousands of patients, has experience with clinical validation, and overwhelmingly positive patient testimonials.
Alex Therapeutics uses its AI-powered digital therapeutics platform “Alex DTx Platform” to develop and launch prescription digital therapies, typically in partnership with pharmaceutical companies. The digital therapeutics products are clinically validated and approved medical devices, prescribed by doctors and reimbursed by healthcare systems. The platform combines evidence-based psychology, primarily Cognitive Behavioral Therapy, with AI and Machine Learning to provide personalized treatments that address the needs of patients worldwide.
%201.png)
